T1D Silver Bullet? Provention Bio Soars On Hopes Teplizumab Is Type 1 Diabetes Game Changer
Executive Summary
Shares in Provention Bio were pushed sharply higher on Monday after news that a two-week course of its experimental immunotherapy teplizumab dramatically reduced type 1 diabetes diagnosis rates in people at high risk for the disease.
You may also be interested in...
EMA Accepts First Diabetes Drug Onto PRIME
Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.
Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.